Ho Jennifer E, Enserro Danielle, Brouwers Frank P, Kizer Jorge R, Shah Sanjiv J, Psaty Bruce M, Bartz Traci M, Santhanakrishnan Rajalakshmi, Lee Douglas S, Chan Cheeling, Liu Kiang, Blaha Michael J, Hillege Hans L, van der Harst Pim, van Gilst Wiek H, Kop Willem J, Gansevoort Ron T, Vasan Ramachandran S, Gardin Julius M, Levy Daniel, Gottdiener John S, de Boer Rudolf A, Larson Martin G
From the Cardiovascular Research Center, Massachusetts General Hospital (J.E.H.); Cardiovascular Medicine Section, Department of Medicine (R.S.) and Section of Preventive Medicine and Epidemiology (R.S.V.), Boston University School of Medicine, MA; National Heart, Lung, and Blood Institute's and Boston University's Framingham Heart Study, MA (J.E.H., R.S.V., D.L., M.G.L.); Department of Mathematics and Statistics, Boston University, MA (D.E., M.G.L.); Department of Cardiology (F.P.B., H.L.H., P.v.d.H., W.H.v.G., R.A.d.B.) and Division of Nephrology, Department of Internal Medicine (R.T.G.), University Medical Center Groningen, The Netherlands; Department of Medicine and Department of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, NY (J.R.K.); Division of Cardiology (S.J.S.), Department of Medicine (C.C., K.L.), and Department of Preventive Medicine (C.C., K.L.), Northwestern University Feinberg School of Medicine, Chicago, IL; Cardiovascular Health Research Unit, Department of Medicine, Department of Epidemiology, and Department of Health Services (B.M.P.) and Department of Biostatistics (T.M.B.), University of Washington; Group Health Research Institute, Group Health Cooperative, Seattle, WA (B.M.P.); Institute for Clinical Evaluative Sciences, Toronto, Canada (D.S.L.); University Health Network, University of Toronto, Canada (D.S.L.); Ciccarone Center for the Prevention of Heart Disease, Johns Hopkins University, Baltimore, MD (M.J.B.); Department of Medicine, Hackensack University Medical Center and Rutgers New Jersey Medical School, Hackensack, NJ (J.M.G.); Center of Research on Psychology in Somatic Diseases, Department of Medical and Clinical Psychology, Tilburg University, Tilburg, The Netherlands (W.J.K.); Population Sciences Branch, Division of Intramural Research, National Heart, Lung, and Blood Institute, Bethesda, MD (D.L.); and Department of Medicine, University of Maryland School of Medicine, Baltimore, MD (J.S.G.). jho
From the Cardiovascular Research Center, Massachusetts General Hospital (J.E.H.); Cardiovascular Medicine Section, Department of Medicine (R.S.) and Section of Preventive Medicine and Epidemiology (R.S.V.), Boston University School of Medicine, MA; National Heart, Lung, and Blood Institute's and Boston University's Framingham Heart Study, MA (J.E.H., R.S.V., D.L., M.G.L.); Department of Mathematics and Statistics, Boston University, MA (D.E., M.G.L.); Department of Cardiology (F.P.B., H.L.H., P.v.d.H., W.H.v.G., R.A.d.B.) and Division of Nephrology, Department of Internal Medicine (R.T.G.), University Medical Center Groningen, The Netherlands; Department of Medicine and Department of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, NY (J.R.K.); Division of Cardiology (S.J.S.), Department of Medicine (C.C., K.L.), and Department of Preventive Medicine (C.C., K.L.), Northwestern University Feinberg School of Medicine, Chicago, IL; Cardiovascular Health Research Unit, Department of Medicine, Department of Epidemiology, and Department of Health Services (B.M.P.) and Department of Biostatistics (T.M.B.), University of Washington; Group Health Research Institute, Group Health Cooperative, Seattle, WA (B.M.P.); Institute for Clinical Evaluative Sciences, Toronto, Canada (D.S.L.); University Health Network, University of Toronto, Canada (D.S.L.); Ciccarone Center for the Prevention of Heart Disease, Johns Hopkins University, Baltimore, MD (M.J.B.); Department of Medicine, Hackensack University Medical Center and Rutgers New Jersey Medical School, Hackensack, NJ (J.M.G.); Center of Research on Psychology in Somatic Diseases, Department of Medical and Clinical Psychology, Tilburg University, Tilburg, The Netherlands (W.J.K.); Population Sciences Branch, Division of Intramural Research, National Heart, Lung, and Blood Institute, Bethesda, MD (D.L.); and Department of Medicine, University of Maryland School of Medicine, Baltimore, MD (J.S.G.).
Circ Heart Fail. 2016 Jun;9(6). doi: 10.1161/CIRCHEARTFAILURE.115.003116.
Heart failure (HF) is a prevalent and deadly disease, and preventive strategies focused on at-risk individuals are needed. Current HF prediction models have not examined HF subtypes. We sought to develop and validate risk prediction models for HF with preserved and reduced ejection fraction (HFpEF, HFrEF).
Of 28,820 participants from 4 community-based cohorts, 982 developed incident HFpEF and 909 HFrEF during a median follow-up of 12 years. Three cohorts were combined, and a 2:1 random split was used for derivation and internal validation, with the fourth cohort as external validation. Models accounted for multiple competing risks (death, other HF subtype, and unclassified HF). The HFpEF-specific model included age, sex, systolic blood pressure, body mass index, antihypertensive treatment, and previous myocardial infarction; it had good discrimination in derivation (c-statistic 0.80; 95% confidence interval [CI], 0.78-0.82) and validation samples (internal: 0.79; 95% CI, 0.77-0.82 and external: 0.76; 95% CI: 0.71-0.80). The HFrEF-specific model additionally included smoking, left ventricular hypertrophy, left bundle branch block, and diabetes mellitus; it had good discrimination in derivation (c-statistic 0.82; 95% CI, 0.80-0.84) and validation samples (internal: 0.80; 95% CI, 0.78-0.83 and external: 0.76; 95% CI, 0.71-0.80). Age was more strongly associated with HFpEF, and male sex, left ventricular hypertrophy, bundle branch block, previous myocardial infarction, and smoking with HFrEF (P value for each comparison ≤0.02).
We describe and validate risk prediction models for HF subtypes and show good discrimination in a large sample. Some risk factors differed between HFpEF and HFrEF, supporting the notion of pathogenetic differences among HF subtypes.
心力衰竭(HF)是一种常见的致命疾病,需要针对高危个体制定预防策略。目前的HF预测模型尚未对HF亚型进行研究。我们试图开发并验证射血分数保留型和降低型心力衰竭(HFpEF、HFrEF)的风险预测模型。
在来自4个社区队列的28820名参与者中,在中位随访12年期间,982人发生了HFpEF,909人发生了HFrEF。将3个队列合并,并采用2:1随机分割用于模型推导和内部验证,第4个队列作为外部验证。模型考虑了多种竞争风险(死亡、其他HF亚型和未分类的HF)。HFpEF特异性模型包括年龄、性别、收缩压、体重指数、抗高血压治疗和既往心肌梗死;其在推导样本(c统计量0.80;95%置信区间[CI],0.78 - 0.82)和验证样本(内部:0.79;95% CI,0.77 - 0.82;外部:0.76;95% CI:0.71 - 0.80)中具有良好的区分度。HFrEF特异性模型还包括吸烟、左心室肥厚、左束支传导阻滞和糖尿病;其在推导样本(c统计量0.82;95% CI,0.80 - 0.84)和验证样本(内部:0.80;95% CI,0.78 - 0.83;外部:0.76;95% CI,0.71 - 0.80)中具有良好的区分度。年龄与HFpEF的相关性更强,而男性、左心室肥厚、束支传导阻滞、既往心肌梗死和吸烟与HFrEF的相关性更强(每次比较的P值≤0.02)。
我们描述并验证了HF亚型的风险预测模型,并在大样本中显示出良好的区分度。HFpEF和HFrEF之间的一些风险因素有所不同,支持了HF亚型之间存在发病机制差异的观点。